Breast Cancer Clinical Trial

Second Echelon Node Study With Methylene Blue

Summary

The investigators plan to study the ability to identify the lymph nodes beyond the sentinel lymph node that may harbor cancer using methylene blue dye.

View Full Description

Full Description

After lymphatic mapping of the SLN with Tc-99 sulfur colloid only, the second-echelon lymphatic mapping was then performed with methylene blue dye by injecting the SLN with 0.05-0.10 cc non dilute methylene blue and tracing via the efferent lymphatic channel to the second echelon lymph node (Figure 1). For our initial patients a 27 gauge needle and 3cc syringe was utilized but this was modified over the study to a 30 gauge needle and 1cc syringe. The blue efferent lymphatic was traced with minimal spreading of the surrounding tissue to visualize its drainage into the next lymph node(s). A second echelon lymph node was considered any blue lymph node or any lymph node with blue dye leading directly into it. The number of second echelon lymph nodes was recorded. The second-echelon lymph node(s) was not removed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed primary cutaneous melanoma located on the extremity or trunk
Patients with clinically stage I-II melanoma
Histologically confirmed invasive ductal or lobular carcinoma
Patient undergoing surgical treatment of breast primary and sentinel lymph node biopsy- clinically node negative

Exclusion Criteria:

Melanoma located on the head or neck, uveal or mucosal
Previous surgery or radiation in or near the sentinel lymph node biopsy nodal basin
Preoperative biopsy proven regional lymph node involvement
Failure of lymphatic mapping with radioactive colloid
Women who are pregnant or nursing
Prior ipsilateral axillary surgery or radiation
Inflammatory breast cancer
No lymph node identified in the ipsilateral breast during pathologic review of the mastectomy specimen
Stage IV breast cancer

Study is for people with:

Breast Cancer

Estimated Enrollment:

21

Study ID:

NCT01823172

Recruitment Status:

Completed

Sponsor:

Mayo Clinic

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

21

Study ID:

NCT01823172

Recruitment Status:

Completed

Sponsor:


Mayo Clinic

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider